XEOMEEN (XEOMIN®) 100u (Spanish)

XEOMEEN® 100u is a botulinum neurotoxin type A product derived from Clostridium botulinum. It is used in both aesthetic medicine and neurological treatments for conditions involving excessive muscle contraction or activity. Unlike other toxins, XEOMEEN is free of complexing proteins, which may reduce the risk of antibody formation over time.

The product comes as a powder for solution for injection and is indicated for facial wrinkles such as glabellar lines, as well as clinical conditions like blepharospasm, cervical dystonia, and spasticity. Its effects begin within a few days and last around 12–16 weeks depending on the treated area and dosage.

XEOMEEN stands out as a pure neurotoxin that does not contain accessory proteins, aiming to offer consistent efficacy and safety for repeated treatments. It is widely used in aesthetic dermatology and neurology.

• High purity formulation: Free from complexing proteins

• Standard potency: 100 Units per vial

• Onset of action: Typically 2–4 days after injection

• Duration: Clinical effect lasts approximately 3–4 months

• Approved for: Both aesthetic and therapeutic applications

XEOMEEN is approved for several therapeutic and aesthetic uses. In aesthetics, it is primarily used for glabellar frown lines in adults. Therapeutically, it helps manage conditions characterized by abnormal muscle tone.

Indications:

• Moderate to severe glabellar lines in adults under 65

• Blepharospasm (uncontrollable eye twitching)

• Cervical dystonia (neck muscle spasms)

• Upper limb spasticity in adults post-stroke

Contraindications:

• Hypersensitivity to botulinum toxin type A

• Presence of infection at injection site

• Diagnosed with myasthenia gravis, Eaton-Lambert syndrome, or ALS

Side Effects:

• Common: Headache, injection site pain, localized muscle weakness

• Aesthetic uses: Eyelid ptosis, dry eyes, swelling at the site

• Neurological uses: Dysphagia, neck pain, voice changes

• Rare: Generalized muscle weakness due to distant toxin spread

XEOMEEN contains botulinum toxin type A, manufactured using a high-purity process that excludes accessory proteins. It is supplied as a lyophilized powder and must be reconstituted with sterile saline prior to use.

• Active ingredient: 100 Units of Clostridium botulinum neurotoxin type A

• Excipients:

  • Human albumin (1 mg)

  • Sucrose (4.7 mg)

• Form: White, preservative-free powder

• Reconstitution volume: Typically 1.25 mL to 2.5 mL NaCl 0.9%

Each vial of XEOMEEN is packaged for single use, ensuring sterility and dosage accuracy. The packaging is suitable for both medical and aesthetic clinic environments.

• 1 vial containing 100 Units of freeze-dried powder

• Glass vial with rubber stopper and aluminum seal

• Supplied in cartons of 1, 2, or 6 vials

• No syringe or diluent included; must be prepared before use

• Includes instruction leaflet in Spanish

XEOMEEN may cause mild to moderate adverse effects, usually limited to the injection site or localized muscles. These are more common in the initial treatments and generally subside within days.

• Injection site reactions: Redness, pain, swelling

• Aesthetic use: Eyelid droop (ptosis), headaches, facial asymmetry

• Therapeutic use: Dysphagia, muscle weakness, hoarseness

• Systemic effects (rare): Generalized botulinum toxin symptoms such as difficulty breathing or swallowing

Proper storage conditions help preserve the potency and safety of botulinum toxin. Both unopened and reconstituted vials require temperature control.

• Unopened vial: Store between 2°C and 8°C (refrigerated)

• Reconstituted solution: Use within 24 hours

• Do not freeze

• Store vial in original packaging to protect from light

• Single-use only; discard remaining product after use